100 mL / 200 mL Preparation Tablets
Useful for smaller assays.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (100 mL / 200 mL Preparation Tablets, 500 mL Preparation Tablets, 1,000 mL / Other Formats), By Application (Cell Culture, Immunoassays & ELISA, Molecular Biology, Histology & Diagnostics, Other Laboratory Uses), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, CROs / CDMOs), By Product Formulation (Standard PBS, PBS-Tween, Specialty / Low-Ionic-Strength PBS), By Packaging (Bottle Packs, Blister / Individual Packs, Bulk Laboratory Packs), and Regional Forecast, 2026-2034
The global phosphate buffered saline PBS tablet market was valued at USD 120.0 million in 2025 and is estimated at USD 125.5 million in 2026. The market is projected to reach USD 180.0 million by 2034, representing a 4.6% CAGR during 2026–2034.
PBS tablets are pre-weighed formulations of phosphate buffer and saline salts designed to produce reproducible phosphate-buffered saline after dissolution in purified water. They eliminate manual weighing and mixing and are widely used in cell culture, immunoassays, molecular biology, histology and diagnostic-reagent preparation.
Commercial formulations vary by final solution volume and composition. Sigma-Aldrich offers tablets that prepare 200 mL of PBS at pH 7.4, while Gibco products prepare 500 mL per tablet and are formulated for cell-culture workflows. Medicago also supplies tablets for 500 mL and 1,000 mL final volumes.
The market benefits from routine laboratory consumption and the convenience of standardized preparation. Growth remains moderate because liquid concentrates and powder sachets are strong substitutes, but tablets retain advantages in portability, shelf storage and low-error buffer preparation.
| Scope | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | 100 mL / 200 mL Preparation Tablets; 500 mL Preparation Tablets; 1,000 mL / Other Formats |
| By Application | Cell Culture; Immunoassays & ELISA; Molecular Biology; Histology & Diagnostics; Other Laboratory Uses |
| By End User | Academic & Research Institutes; Pharmaceutical & Biotechnology Companies; Diagnostic Laboratories; CROs / CDMOs |
| By Product Formulation | Standard PBS; PBS-Tween; Specialty / Low-Ionic-Strength PBS |
| By Packaging | Bottle Packs; Blister / Individual Packs; Bulk Laboratory Packs |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
The market includes pre-weighed PBS tablets designed to dissolve in a specified volume of water to produce laboratory phosphate-buffered saline.
Ready-made liquid PBS, powder sachets and other biological buffers are outside the core tablet revenue boundary.
PBS is used daily in cell washing, dilution, immunoassays and sample handling.
Pre-weighed tablets reduce weighing errors and simplify preparation.
Ready-to-use PBS and concentrates limit tablet penetration in high-volume labs.
Growth in cell biology, diagnostics and bioprocess research supports demand.
Users select products by pH, ionic strength, detergent content and calcium/magnesium composition.
500 mL and 1,000 mL formats improve routine laboratory convenience.
Tablets with Tween 20 support ELISA and western-blot washing.
Calcium- and magnesium-free formulations remain important.
Biopharma and diagnostics users seek controlled-grade reagents.
Laboratory reagents are increasingly sourced through digital catalogs.
PBS tablet performance depends on exact salt composition, rapid dissolution, final pH and reproducible ionic strength.
Phosphate + Sodium Chloride
Maintains physiological pH and osmotic conditions.
KCl
Supports standard PBS ionic composition.
Tween 20
Reduces nonspecific binding in immunoassay wash buffers.
Pre-Weighed Compressed Format
Eliminates routine weighing and mixing.
The market is segmented by final preparation volume. 500 mL tablets represent a major commercial format.
Useful for smaller assays.
Common in cell culture and immunoassay laboratories.
Support higher-volume laboratories.
500 mL and 1,000 mL formats should capture the strongest routine demand.
Applications include cell culture, immunoassays, molecular biology, histology and diagnostics.
Used for washing cells, transport and reagent preparation.
PBS and PBS-Tween are standard wash and dilution buffers.
Used for sample dilution and protein workflows.
Supports washing, staining and sample handling.
Includes microscopy, chromatography and general biochemical workflows.
Cell culture and immunoassays will remain the largest applications.
Academic institutes, biopharma companies, diagnostic labs and CROs are the main end users.
Universities use PBS across teaching and research labs.
Biopharma labs require reproducible high-purity buffers.
PBS supports assay and sample preparation.
Contract labs use standardized buffers for multi-client work.
Academic labs will remain the largest user base, while biopharma supports premium grades.
Standard PBS, PBS-Tween and specialty formulations address different workflows.
Used broadly across cell and molecular biology.
Adds nonionic detergent for washing and blocking.
Supports niche assays with specific ionic requirements.
Standard PBS will remain dominant, while PBS-Tween provides strong specialty demand.
Bottle packs, individual packs and bulk laboratory packs shape procurement.
100-tablet bottles are common and easy to store.
Individual packing improves moisture protection.
Bulk packaging reduces unit cost for large labs.
Bottle packs should remain the leading presentation.
Regional demand follows life-science research intensity, diagnostic testing and biopharma laboratory infrastructure. North America is the largest market.
The United States and Canada have dense academic, biotech and diagnostic laboratory networks. United States: Broad commercial availability supports routine use.
Strong academic and biopharma research supports stable demand.
China, India, Japan and South Korea are expanding life-science and diagnostic capacity. China & India: Research and biopharma expansion increases reagent consumption.
Growth follows academic and diagnostic laboratory expansion.
Demand is concentrated in universities, hospitals and advanced research centers.
PBS tablets are generally laboratory reagents, so buyers focus on specification control, grade and reproducibility.
Many commercial PBS tablets are sold for laboratory research use. Defines intended market.
Products commonly target pH near 7.4 after dissolution. Supports biological compatibility.
Standard formulations specify phosphate, sodium chloride and potassium chloride. Supports reproducibility.
PBS-Tween and calcium/magnesium-free products serve application-specific needs. Broadens portfolio value.
The market is fragmented across global laboratory-reagent companies and regional buffer specialists.
Thermo Fisher Scientific & Merck / Sigma-Aldrich
Large catalogs, documentation and distribution support adoption.
Medicago
Pre-weighed 500 mL and 1,000 mL tablets target immunology and microbiology labs.
Spectrum, Bio Basic, Takara Bio & Others
Compete on pricing and pack sizes.
2026: Thermo Fisher continued marketing Gibco PBS tablets in 100-tablet packs with 500 mL preparation per tablet.
2026: Sigma-Aldrich continued supplying P4417 PBS tablets for 200 mL preparations at pH 7.4.
Current product cycle: Suppliers continue differentiating through PBS-Tween, high-purity and larger-volume tablet formats.
Growth is expected to remain steady as cell culture, immunoassay and molecular-biology activity expands and laboratories value pre-weighed preparation. The market is estimated at USD 125.5 million in 2026 and projected to reach USD 180.0 million by 2034 at a 4.6% CAGR.
Routine washing and dilution support repeat demand. Sustains volume.
PBS-Tween expands assay-specific use. Adds specialty demand.
High-purity standardized buffers gain value. Supports premium products.
Pre-weighed tablets reduce preparation error. Supports adoption.
Liquid and powder PBS limit faster growth. Keeps CAGR moderate.
This report covers the phosphate buffered saline pbs tablet market across type, application, end-user, formulation and packaging segmentation, major regions, selected countries, competitive positioning, current developments and the 2026–2034 market outlook.
The analysis combines current market-size evidence with primary product specifications from leading laboratory-reagent suppliers. The displayed 2026 and 2034 values are consistent with a 4.6% CAGR.
The assessment emphasizes consistent market boundaries, current product evidence, primary regulatory or scientific sources, and arithmetic consistency across the displayed forecast values.
USD 120.0 million in 2025, USD 125.5 million in 2026 and USD 180.0 million by 2034.
They prepare standardized phosphate-buffered saline for cell culture, immunoassays and laboratory work.
Cell culture and immunoassay workflows are major applications.
North America.
pH 7.4 is a common final specification.
Commercial products prepare volumes such as 200 mL, 500 mL or 1,000 mL.
It is PBS containing Tween 20 for immunoassay washing.
Thermo Fisher, Merck/Sigma-Aldrich, Medicago and other reagent suppliers.
2026–2034, with 2025 as the base year.
Sigma-Aldrich — Phosphate Buffered Saline Tablet P4417. 200 mL preparation and pH specification
Thermo Fisher Scientific — Gibco PBS Tablets. 500 mL preparation and cell-culture use
Medicago / Fisher Scientific — PBS Tablets pH 7.4. 500 mL and 1,000 mL formats
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.